{"title":"胃癌患者c-MET蛋白表达的预后价值：系统回顾和荟萃分析。","authors":"Qianni Yang, Xiaodong Han","doi":"10.1080/1354750X.2025.2544556","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The heterogeneous nature of c-MET overexpression in gastric cancer (GC) leads to a lack of consensus on its prognostic significance.</p><p><strong>Objective: </strong>To evaluate the predictive value of c-MET protein expression in gastric cancer patients.</p><p><strong>Methods: </strong>A systematic review of studies from PubMed, Web of Science, Embase, and Cochrane Library up to April 2025. Heterogeneity and robustness were assessed using the Cochrane Q test, I<sup>2</sup> statistic, and sensitivity analysis. Publication bias was evaluated with Egger's and Begg's tests. The Newcastle-Ottawa Scale (NOS) assessed methodological quality.</p><p><strong>Results: </strong>From 2,322 articles, 22 studies were included. High c-MET expression was significantly associated with reduced overall survival (OS) (Hazard Ratio [HR] = 1.22; 95% Confidence Interval [CI]: 1.13, 1.31; I<sup>2</sup> = 6.8%; P = 0.371) and disease-free survival (DFS) (pooled HR = 1.39; 95% CI: 1.11, 1.68; I<sup>2</sup> = 42.4%; P = 0.139). Definitions of c-MET positivity varied across studies regarding thresholds, staining intensity, and detection methods. Subgroup analysis of OS revealed conflicting conclusions based on study design, cutoff values, and c-MET assays.</p><p><strong>Conclusion: </strong>High c-MET expression may independently predict poor GC prognosis. Future efforts should focus on standardized detection methods and high-quality prospective studies to validate its prognostic value.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"1-10"},"PeriodicalIF":1.9000,"publicationDate":"2025-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prognostic value of c-MET protein expression in gastric cancer patients: a systematic review and meta-analysis.\",\"authors\":\"Qianni Yang, Xiaodong Han\",\"doi\":\"10.1080/1354750X.2025.2544556\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The heterogeneous nature of c-MET overexpression in gastric cancer (GC) leads to a lack of consensus on its prognostic significance.</p><p><strong>Objective: </strong>To evaluate the predictive value of c-MET protein expression in gastric cancer patients.</p><p><strong>Methods: </strong>A systematic review of studies from PubMed, Web of Science, Embase, and Cochrane Library up to April 2025. Heterogeneity and robustness were assessed using the Cochrane Q test, I<sup>2</sup> statistic, and sensitivity analysis. Publication bias was evaluated with Egger's and Begg's tests. The Newcastle-Ottawa Scale (NOS) assessed methodological quality.</p><p><strong>Results: </strong>From 2,322 articles, 22 studies were included. High c-MET expression was significantly associated with reduced overall survival (OS) (Hazard Ratio [HR] = 1.22; 95% Confidence Interval [CI]: 1.13, 1.31; I<sup>2</sup> = 6.8%; P = 0.371) and disease-free survival (DFS) (pooled HR = 1.39; 95% CI: 1.11, 1.68; I<sup>2</sup> = 42.4%; P = 0.139). Definitions of c-MET positivity varied across studies regarding thresholds, staining intensity, and detection methods. Subgroup analysis of OS revealed conflicting conclusions based on study design, cutoff values, and c-MET assays.</p><p><strong>Conclusion: </strong>High c-MET expression may independently predict poor GC prognosis. Future efforts should focus on standardized detection methods and high-quality prospective studies to validate its prognostic value.</p>\",\"PeriodicalId\":8921,\"journal\":{\"name\":\"Biomarkers\",\"volume\":\" \",\"pages\":\"1-10\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-08-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomarkers\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/1354750X.2025.2544556\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1354750X.2025.2544556","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
Prognostic value of c-MET protein expression in gastric cancer patients: a systematic review and meta-analysis.
Background: The heterogeneous nature of c-MET overexpression in gastric cancer (GC) leads to a lack of consensus on its prognostic significance.
Objective: To evaluate the predictive value of c-MET protein expression in gastric cancer patients.
Methods: A systematic review of studies from PubMed, Web of Science, Embase, and Cochrane Library up to April 2025. Heterogeneity and robustness were assessed using the Cochrane Q test, I2 statistic, and sensitivity analysis. Publication bias was evaluated with Egger's and Begg's tests. The Newcastle-Ottawa Scale (NOS) assessed methodological quality.
Results: From 2,322 articles, 22 studies were included. High c-MET expression was significantly associated with reduced overall survival (OS) (Hazard Ratio [HR] = 1.22; 95% Confidence Interval [CI]: 1.13, 1.31; I2 = 6.8%; P = 0.371) and disease-free survival (DFS) (pooled HR = 1.39; 95% CI: 1.11, 1.68; I2 = 42.4%; P = 0.139). Definitions of c-MET positivity varied across studies regarding thresholds, staining intensity, and detection methods. Subgroup analysis of OS revealed conflicting conclusions based on study design, cutoff values, and c-MET assays.
Conclusion: High c-MET expression may independently predict poor GC prognosis. Future efforts should focus on standardized detection methods and high-quality prospective studies to validate its prognostic value.
期刊介绍：
The journal Biomarkers brings together all aspects of the rapidly growing field of biomarker research, encompassing their various uses and applications in one essential source.
Biomarkers provides a vital forum for the exchange of ideas and concepts in all areas of biomarker research. High quality papers in four main areas are accepted and manuscripts describing novel biomarkers and their subsequent validation are especially encouraged:
• Biomarkers of disease
• Biomarkers of exposure
• Biomarkers of response
• Biomarkers of susceptibility
Manuscripts can describe biomarkers measured in humans or other animals in vivo or in vitro. Biomarkers will consider publishing negative data from studies of biomarkers of susceptibility in human populations.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
